
    
      This study will investigate if long-term treatment with suvorexant will slow amyloid-β
      accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to
      Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of
      amyloid-beta detected on brain scans (primary outcome).
    
  